Morgan Stanley Bei Gene, Ltd. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Morgan Stanley holds 268,474 shares of BGNE stock, worth $60.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

268,474

Previous 411,929 34.83%

Holding current value

$60.9 Million

Previous $93.4 Million 34.83%

% of portfolio

0.0%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	N/A	-143,455 Reduced 34.83%	268,474 $60.9 Million
Q1 2025 May 15, 2025	SELL	$175.1 - $226.71 $57.1 Million - $74 Million	-326,211 Reduced 44.19%	411,929 $93.4 Million
Q4 2024 Feb 14, 2025	BUY	$174.72 - $246.04 $98.7 Million - $139 Million	565,108 Added 326.59%	738,140 $136 Million
Q3 2024 May 14, 2025	BUY	$143.93 - $224.51 $12.6 Million - $19.6 Million	87,199 Added 101.59%	173,032 $38.8 Million
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $12.6 Million - $19.6 Million	87,199 Added 101.59%	173,032 $38.8 Million
Q2 2024 May 14, 2025	SELL	$129.52 - $174.32 $84.5 Million - $114 Million	-652,307 Reduced 88.37%	85,833 $12.2 Million
Q2 2024 Oct 17, 2024	SELL	$129.52 - $174.32 $4.79 Million - $6.44 Million	-36,945 Reduced 30.09%	85,833 $12.2 Million
Q2 2024 Aug 14, 2024	SELL	$129.52 - $174.32 $4.79 Million - $6.44 Million	-36,945 Reduced 30.09%	85,833 $12.2 Million
Q1 2024 Oct 17, 2024	BUY	$141.8 - $181.47 $5.24 Million - $6.7 Million	36,945 Added 43.04%	122,778 $19.2 Million
Q1 2024 Aug 16, 2024	SELL	$141.8 - $181.47 $5.42 Million - $6.94 Million	-38,256 Reduced 23.76%	122,778 $19.2 Million
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $5.42 Million - $6.94 Million	-38,256 Reduced 23.76%	122,778 $19.2 Million
Q4 2023 Aug 16, 2024	BUY	$158.67 - $201.58 $11.9 Million - $15.2 Million	75,201 Added 87.61%	161,034 $29 Million
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $2.45 Million - $3.11 Million	15,452 Added 10.61%	161,034 $29 Million
Q3 2023 Nov 15, 2023	SELL	$179.87 - $225.13 $6.43 Million - $8.05 Million	-35,761 Reduced 19.72%	145,582 $26.2 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $4.54 Million - $6.79 Million	25,437 Added 16.32%	181,343 $32.3 Million
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $5.55 Million - $7.07 Million	-25,771 Reduced 14.19%	155,906 $33.6 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $1.18 Million - $2.16 Million	-9,413 Reduced 4.93%	181,677 $40 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $6.3 Million - $9.67 Million	47,833 Added 33.39%	191,090 $25.8 Million
Q2 2022 Oct 27, 2022	BUY	$121.11 - $216.05 $3.07 Million - $5.47 Million	25,328 Added 21.48%	143,257 $23.2 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $3.07 Million - $5.47 Million	25,328 Added 21.48%	143,257 $23.2 Million
Q1 2022 Oct 27, 2022	SELL	$146.52 - $269.56 $3.71 Million - $6.83 Million	-25,328 Reduced 17.68%	117,929 $22.2 Million
Q1 2022 May 13, 2022	SELL	$146.52 - $269.56 $5.39 Million - $9.92 Million	-36,815 Reduced 23.79%	117,929 $22.2 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $6.67 Million - $10.4 Million	26,820 Added 20.97%	154,744 $41.9 Million
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $31.9 Million - $51.6 Million	127,924 New	127,924 $46.4 Million

Others Institutions Holding BGNE

# of Institutions

269

Shares Held

32.2M

Call Options Held

113K

Put Options Held

106K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account